PRIVACY NOTICE

Effective Date: March 4, 2025

Introduction

At Rubedo Life Sciences (“we,” “our,” “us”), we are committed to protecting and respecting your privacy. This Privacy Notice explains how we collect, use, disclose, and safeguard Personal Data from individuals (“you” or “your”) when you visit our website (including rubedolife.com) and you interact with us or our services (our “Services”), in accordance with applicable data protection laws.

As used in this Privacy Notice, “Personal Data” means any information relating to an identified or identifiable individual. Please read this Privacy Notice carefully to understand how we handle your Personal Data. By using our Services, you agree to the collection, use, disclosure, and procedures described in this Privacy Notice.

Sources of Personal Data Collected

We may collect a variety of Personal Data from or about you or your devices from various sources, as described below. Where applicable, we indicate whether and why you must provide us with your Personal Data, as well as the consequences of failing to do so. If you do not provide your Personal Data when requested, you may not be able to use our Services if that Personal Data is necessary to provide you with our Services or if we are legally required to collect it.

We collect personal data about you from the following sources:

  • Directly from you – We may collect Personal Data that you directly provide to us such as when you participate in our clinical trials, you interact with us in person, in webinars/webcasts or trade shows and conferences, or when you apply to our jobs.
  • Automatically – Through cookies and analytics when you visit our website as described in our Cookie Policy
  • From third parties – Including healthcare providers, business partners, regulatory authorities, and our vendors.

  • From publicly available sources – we may collect Personal Data from publicly available sources such as clinicaltrials.gov to ensure we conduct the proper due diligence on physicians, health care professionals and others for purposes of clinical trials.

Categories of Personal Data We Process

We process the following categories of personal data:

Categories of Personal Data

Examples

Contact Information

Name, email address, phone number, postal address, username and password (where applicable).

Professional Information

Job title, employer, industry, and professional qualifications.

Financial Information

Bank account details for processing payments, invoicing details, and payment history (where applicable).

Health Information

Personal health data, clinical trial data, medical conditions, and genetic data (where required for research or clinical trials).

Technical Data

IP addresses, browser type, operating system version, application installations, device identifiers, cookies, data from user tracking and usage data.

CV Data

Resumes, reference letters, employment history (where applicable)

Optional Data

Any Personal Data that you may voluntarily provide to us

Purpose of Processing Personal Data

We collect and process Personal Data for the following purposes:

Processing of Personal Data

Purposes

Clinical Trials & Research

To identify clinical trial sites, investigators and for the purpose of conducting clinical trials, medical research, and the analysis of clinical data.

Regulatory Compliance

To comply with our legal and regulatory obligations, including reporting requirements to health authorities, enforcing our legal rights, or as may be required by applicable laws and regulations or requested by any judicial process or governmental agency.

Product awareness

To share company informational materials, to collaborate with healthcare professionals, to submit medical publications and other communications.

Provide Services

To provide our website, and otherwise to make our Services available to you

Contractual Performance

To fulfill contractual obligations arising from our relationship with you or your employer

Communication

To communicate with you, provide you with updates and other information relating to our Services, provide information that you request, respond to comments and questions, and otherwise provide support;

AI-Assisted Drug Selection

To identify potential drug compounds. AI-driven insights are always subject to several sets of human reviews.

Security & protection of rights

To protect our business, ensuring security and preventing fraud and abuse, unauthorized access and misuse.

Business purposes

For our everyday business purposes, including for internal product testing, to develop new products, services, features and functionality, for recruitment practices and responding to your requests

Aggregate/Anonymize

To generate anonymized or aggregate data containing only de-identified, non-Personal Data that we may use for any lawful purposes.

Other Purposes

For other purposes for which we provide specific notice at the time the information is collected.

Legal Bases for Processing European Personal Data

If you are located in the European Economic Area (“EEA”), the United Kingdom (“UK”), or Switzerland, we only process your Personal Data when we have a valid “legal basis,” including as set forth below.

  • Consent. We may process your Personal Data where you have consented to certain processing of your Personal Data.
  • Contractual Necessity. We may process your Personal Data where required to provide you with the Services. For example, we may need to process your Personal Data to respond to your inquiries or requests.
  • Compliance with a Legal Obligation. We may process your Personal Data where we have a legal obligation to do so. For example, we may process your Personal Data to comply with tax, labor and accounting obligations.
  • Legitimate Interests. We may process your Personal Data where we or a third party have a legitimate interest in processing your Personal Data. Specifically, we have a legitimate interest in using your Personal Data for product development and internal analytics purposes, and otherwise to improve the safety, security, and performance of the Services. We only rely on our or a third party’s legitimate interests to process your Personal Data when these interests are not overridden by your rights and interests.
  • Processing of special categories of Personal Data. We may process special categories of Personal Data (as defined under Article 9 of the EU/UK General Data Protection Regulation). When doing so, we will rely on an appropriate legal basis for special categories of Personal Data, including: (i) your explicit consent; (ii) processing is necessary to carry out the obligations and exercise specific rights in the field of employment and social security and social protection law; (iii) processing is necessary to protect applicable vital interests; (iv) processing relates to Personal Data which are manifestly made public; (v) processing is necessary for the establishment, exercise or defense of legal claims; (vi) processing is necessary for reasons of substantial public interest; (vii) processing is necessary for the purposes of preventive or occupational medicine, for the assessment of the working capacity of the employee, medical diagnosis, the provision of health or social care or treatment or management of health or social care systems and services; (viii) processing is necessary for reasons of public interest in the area of public health; or (ix) processing is necessary for archiving purposes in the public interest, scientific or historical research purposes or statistical purposes.

Sharing of Personal Data

We may share your personal data with the following recipients:

  • Affiliates and Subsidiaries: We may disclose any Personal Data we receive to our current or future partners and affiliates within the Rubedo Life Sciences group for any of the purposes described in this Privacy Notice.
  • Service Providers: We may disclose any Personal Data we receive to third-party service providers who assist with clinical trials, laboratories, research, data analytics, IT support, and communication.
  • As required by Law and Regulatory Authorities: We may access, preserve, and disclose your Personal Data if we believe doing so is required or appropriate to comply with law enforcement requests and legal process, such as a court order or subpoena, to respond to health authorities, regulatory bodies, and government agencies, to respond to your requests, or protect your, our, or others’ rights, property, or safety.
  • Professional Consultants: Lawyers, accountants, medical advisors, auditors and other consultants who provide legal, financial and professional services to us.
  • Business Partners: Trusted business partners with whom we collaborate on initiatives, with your consent where necessary.
  • Merger, Sale, or Other Asset Transfers. We may transfer your Personal Data to service providers, advisors, potential transactional partners, or other third parties in connection with the consideration, negotiation, or completion of a corporate transaction in which we are acquired by or merged with another company, or we sell, liquidate, or transfer all or a portion of our assets.
  • Consent. We may also disclose your Personal Data with your permission.

International Transfers of Personal Data

Our Services are hosted in the United States. If you choose to use the Services from the EEA, the UK, Switzerland or other regions of the world with laws governing data collection and use that may differ from U.S. law, then please note that you are transferring your Personal Data outside of those regions to the U.S. for storage and processing. We may transfer Personal Data from the EEA, the UK or Switzerland to the U.S. and other third countries based on European Commission-approved or UK Government-approved Standard Contractual Clauses, or otherwise in accordance with applicable data protection laws. We may also transfer your data from the U.S. to other countries or regions in connection with storage and processing of data, fulfilling your requests, and operating the Services. For more information about the tools that we use to transfer Personal Data, or to obtain a copy of the contractual safeguards we use for such transfers (if applicable), you can contact us as described below.

Your Rights

If you are located in the EEA, the UK or Switzerland, you have the following rights regarding your Personal Data:

  • Right to Access: You have the right to request access to your Personal Data that we process.
  • Right to Rectification: You have the right to request the correction or update of inaccurate or incomplete Personal Data.
  • Right to Erasure: You have the right to request the deletion of your Personal Data in certain circumstances.
  • Right to Restriction of Processing: You have the right to request that we restrict the processing of your Personal Data in certain situations.
  • Right to Data Portability: You have the right to receive your Personal Data in a structured, commonly used, and machine-readable format, and to transfer it to another controller.
  • Right to Object: You have the right to object to the processing of your Personal Data in certain circumstances.
  • Right to Withdraw Consent: Where processing is based on consent, you have the right to withdraw your consent at any time and free of charge. We will apply your preferences going forward and this will not affect the lawfulness of the processing before you withdrew your consent.
  • Right to Lodge a Complaint: You have the right to lodge a complaint with a supervisory authority, including in your country of residence, place of work or where an incident took place.


To exercise any of your rights, please contact us at the details provided at the end of this Privacy Notice. Before fulfilling your request, we may ask you to provide reasonable information to verify your identity. Please note that there are exceptions and limitations to each of these rights, and that while any changes you make will be reflected in active user databases instantly or within a reasonable period of time, we may retain Personal Data for backups, archiving, prevention of fraud and abuse, analytics, satisfaction of legal obligations, or where we otherwise reasonably believe that we have a legitimate reason to do so.

Automated Decision-Making

As part of our commitment to innovation and precision medicine, we use Artificial Intelligence (AI) and machine learning algorithms to assist in drug selection. These technologies analyze large datasets, including clinical trial results, genetic information, and patient responses, to identify potential drug compounds. The AI models operate under strict oversight, ensuring compliance with applicable data protection laws, which governs automated decision-making. Any Personal Data processed through AI systems is pseudonymized or anonymized where possible, and human experts always review and perform rigorous testing of AI-driven insights before final decisions are made. If you are located in the EEA, the UK or Switzerland, and to the extent that our processing operations are classified as automated decision-making, you have the right not to be subject to a decision based solely on automated processing, including profiling, which produces legal effects concerning you or similarly significantly affect you. This right will not apply if the decision: (i) is necessary for entering into, or performance of, a contract between you and us; (ii) is authorized by EU or UK applicable law to which we are subject and which also lays down suitable measures to safeguard the data subject’s rights and freedoms and legitimate interests; or (iii) is based on your explicit consent.

Security of Personal Data

We make reasonable efforts to protect your Personal Data against unauthorized or unlawful processing, accidental loss, destruction, or damage by using technical and organizational measures designed to safeguard the Personal Data we maintain. This includes encryption, access control, and secure storage practices. However, because no electronic transmission or storage of information can be entirely secure, we can make no guarantees as to the security or privacy of your Personal Data.

Third Parties

Our Services may contain links to other websites, products, or services that we do not own or operate. We are not responsible for the privacy practices of these third parties. Please be aware that this Privacy Notice does not apply to your activities on these third-party services or any information you disclose to these third parties. We encourage you to read their privacy policies before providing any information to them.

Children’s Privacy

We do not knowingly collect, maintain, or use Personal Data from individuals under 18 years of age, and no part of our Services is directed to children. If you learn that a child has provided us with Personal Data in violation of this Privacy Notice, then you may alert us at: [email protected]

Data Retention

We retain your Personal Data for no longer than is necessary for the purposes for which it was collected. When you request that we do so, we take measures to delete your Personal Data or keep it in a form that does not permit identifying you when this Personal Data is no longer necessary for the purposes for which we process it, unless we are required by law to keep this information for a longer period. When we process Personal Data for our own purposes, we determine the retention period taking into account various criteria, such as the type of services provided to you, the nature and length of our relationship with you, possible re-enrollment with the Services, the impact on the Services we provide to you if we delete some Personal Data from or about you, and mandatory retention periods provided by law and the statute of limitations. In some cases, we may retain your Personal Data for longer periods, such as when required by law or in the context of ongoing research or clinical trials.

Changes to This Privacy Notice

We may update this Privacy Notice from time to time. When we do, we will post the updated notice on our website and update the “Effective Date” at the top of this notice. Please review this notice periodically to stay informed about how we are protecting your Personal Data. If we make a material update, we may notify you of such update through our Services, by email, or other means.

Contact Us

Rubedo Life Sciences Inc. is responsible and the data controller for processing your Personal Data. If you have any questions or concerns about this Privacy Notice or our data processing practices, please contact us:

Rubedo Life Sciences, Inc.
428 Oakmead Pkwy
Sunnyvale, CA 94085
[email protected]

Copyright 2025 by Rubedo Life Sciences, Inc.

privacy policy
cookie policy
Terms of service
Linkedin

Julianne Averill

Chief Financial Officer

Julianne Averill is a dynamic biotech CFO and business strategist with 20+ years of experience driving innovation in finance across organizations such as Deloitte, Manifest MedEx, and Neumora Therapeutics. Currently a Managing Director & CFO at Danforth Advisors, she leads growth for the San Francisco region, advising boards and investors on funding strategies and leading transformative product & service launches. Her expertise has facilitated over $11 billion in fundraising and M&A initiatives and has led to the worldwide adoption of many AI-enabled digital health & biopharma products designed to improve patient outcomes. Beyond her professional role, Julianne is active in nonprofit board leadership and serves on the boards of CureSearch and the Junior League; further, she is an operating advisor to How Women Invest, a venture fund focused on changing the venture landscape. Julianne holds B.S. and M.S. degrees in business administration from CSU Fresno, a business analytics certificate from Harvard, and is a CPA, SHRM-CP, & NACD.DC. 

Robert Gould, PhD

Robert Gould, PhD Khosla Venture Partner

Robert is an Operating Partner at Khosla Ventures with focus on health care. He has over 30 years of industry and management experience. Robert serves on the boards of Faeth Therapeutics, Fulcrum Therapeutics, Turnstone Biologics, HemoShear Therapeutics and Spring Arbor University.

Prior to joining Khosla Ventures, Robert was President and Chief Executive Officer of Fulcrum Therapeutics from 2016 the year the company was founded until his retirement in March 2021.  From 2010 to 2015, Robert served as president and CEO of Epizyme, an oncology drug discovery and development company.  Prior to joining Epizyme, Robert served as the director of novel therapeutics at Broad Institute of MIT and Harvard from 2006 to 2010.  Robert began his career at Merck where he held a variety of leadership positions over 23 years, culminating in his role as vice president, licensing and external research.

During his career, Robert has been instrumental in advancing more than 20 compounds from discovery into clinical development in multiple therapeutic areas.  

Robert holds a bachelor’s degree in chemistry from Spring Arbor University and a Ph.D. in biochemistry from the University of Iowa. He completed postdoctoral studies at Johns Hopkins University.

Marco Quarta, PhD

Co-Founder and Chief Scientific Officer

Marco Quarta, PhD, he is the founding CEO and President of Rubedo that he led from 2018 to 2024.  He received his doctorate degree in Biotechnology from the University of Bologna and a Ph.D. in Neuroscience from the University of Padua. He completed a post-doc in Aging and Stem cell Biology in the lab of Prof. Thomas Rando at Stanford University. He continued his work at Stanford directing a research team at the Center for Tissue Regeneration, Repair, and Restoration at the VA Hospital in Palo Alto, CA. While there, he established a translational program in regenerative medicine. He has over 35 publications and patents in the field of aging, stem cells, regenerative medicine, and rejuvenation.Marco also co-founded Wetware Concepts, YEBN, and Turn Biotechnology and served as an executive board member of the European Federation of Biotechnologies. He currently sits on the advisory board of the California Institute for Regenerative Medicine (CIRM) Calpoly Bridge program, and the advisory board at the Center for Healthcare Innovation. Marco is a member of the Paul F Glenn Center for the Biology of Aging Studies at Stanford University, one of the most prestigious institutions supporting the science of aging. He is President and co-founder of the scientific organization Phaedon Institute, focused on Longevity Medicine.

Judith Campisi, PhD

https://www.nature.com/articles/s43587-024-00603-5

Buck Institute for Research & Aging Professor, Biogerontology

Judith Campisi received a PhD in biochemistry from the State University of New York Stony Brook, and postdoctoral training in cancer biology at the Dana-Farber Cancer Institute and Harvard Medical School. In 1984, she joined the Boston University Medical School faculty as Assistant and Associate Professor. She joined the Lawrence Berkeley National Laboratory as Senior Scientist in 1991. In 2002, she started a second laboratory at the Buck Institute for Research on Aging, where she is Professor. At both institutions, Campisi established a broad program to understand the relationship between aging and disease, with an emphasis on the role of cellular senescence in promoting inflammation, cancer, and degenerative diseases. Her laboratory made pioneering discoveries in these areas, and continues to challenge and alter existing paradigms. She has several long-standing national and international collaborations, and she mentors many students and fellows. Campisi received numerous awards, including MERIT awards from the National Institute on Aging, and awards from the AlliedSignal Corporation, Gerontological Society of America and American Federation for Aging Research, the Longevity prize from the IPSEN Foundation, and the first international Olav Thon Foundation prize. She is an elected fellow of the American Association for the Advancement of Science, American Association for Cancer Research, and the US National Academy of Sciences. She serves on numerous national and international editorial and scientific advisory boards.

mark gallop,phd

Co-Founder, Chairman Chemistry and Development

Mark Gallop is Executive-in-Residence at 5AM Venture Partners, LLC. He consults with emerging biotechnology companies in oncology, neuroscience, gastrointestinal disorders and drug design on drug discovery technologies and strategies. From 2012 to 2017 he served as the founding Chief Scientific Officer at Nurix, Inc., a venture-backed discovery company formed to explore drug development targeting ubiquitin ligase enzymes, with therapeutic applications spanning across oncology, immunology, inflammation and immuno-oncology. Prior to joining Nurix, he was Senior Vice President of Research and XenoPort, Inc., a company he co-founded in 1999 with the mission of improving the clinical utility of medicines by exploiting active transport mechanisms to optimize their pharmacokinetic properties. While at XenoPort, his team discovered Horizant™, a prodrug of gabapentin that was approved by the FDA in 2011 and the MHW in Japan in 2012 for the treatment of restless legs syndrome. Previously, Dr. Gallop was Senior Director of Combinatorial Chemistry at Affymax. He is recognized as an early pioneer and international expert in solid-phase combinatorial chemistry. He was a recipient of the ACROS award of the Belgian Organic Synthesis Symposium in 1996 for his outstanding contributions to this field. He is an inventor on more than 100 issued or pending U.S., and PCT patents and an author of over 60 manuscripts in peer-reviewed journals. In 1994, he co-authored a landmark review of the then-emerging field of combinatorial chemistry that has subsequently become one of the most highly cited papers in chemistry. After undergraduate studies in New Zealand, he obtained his Ph.D. degrees in inorganic chemistry from the University of Cambridge and was a Lindemann postdoctoral fellow in the laboratories of Profs. Peter G. Schultz and Robert G. Bergman at the University of California, Berkeley.

OFIR MORENO, PHD

OFIR MORENO, PHD SVP Drug Discovery

A veteran biotech executive, with a passion for integrating advanced techniques and technologies towards the discovery and development of new drugs. Demonstrated success discovering novel small molecule drugs and targeted drug conjugates utilizing a variety of technological platforms and the application of model informed drugs. He held leading roles at MEI Pharma, Znomics, Dendreon, Amgen and Merck.

ALBERTO VITARI, PhD

Senior Director, Discovery Research

Alberto Vitari, PhD has extensive and diverse experience driving and delivering target identification and validation programs. He is proficient in cancer genomics, functional genetics and leveraging bioinformatics tools to identify novel targets that serve as a basis for drug development. ​Prior to Rubedo Life Sciences, he was Group Leader, Molecular and Cellular Biology at Verily (formerly Google Life Sciences) and​ Group Leader at Novartis Institutes for BioMedical Research. At Novartis, Alberto was responsible for the identification of novel oncology molecular targets. He has expertise in cell signaling, cancer genetics, mechanism of action elucidation, and data integration to guide patient selection. ​He served as a postdoctoral scientist at Genentech and at Pharmacy Corporation in Italy. His scientific record includes top tier publications in Cell, Science, and Nature, including a seminal work on proto-oncogenic factors (Vitari et al., Nature, 2011).

alex laslavic, PhD

Chief Technology Officer

Alex Laslavic is an experienced software engineer and team lead. His focus has been in building and leading software and systems engineering teams, designing and building infrastructure software and distributed systems, and building pipelines for large-scale data analysis. Before joining Rubedo Alex was a Team Lead at Facebook, and before that a Lead Engineer at CNN and Turner Broadcasting. Alex is passionate about leveraging his computational skills to help drive advances in aging therapeutics and regenerative medicine.

julian klein

Co-Founder, Research

Julian Klein holds a B.Sc. degree in Biotechnology (Germany) and a M.Sc. in Molecular Medicine (Erasmus University, Netherlands). He completed his graduate program at Stanford University where he focused on aging biology and received certification for completion of Harvard Business School pre-MBA program. The Glenn Foundation for Medical Research has funded his studies on age-related diseases, specifically his work on antisense oligonucleotides targeting muscle stem cells for the treatment of sarcopenia. Previously, he had been involved in the development of a cell permeable peptide for the treatment of cellular senescence in the context of chronic kidney disease and chemotherapy. His results were published in the prestigious Journal Cell (Baar et at, 2017). The study has drawn worldwide public attention, and ignited a venture-backed company, Cleara Biotech, aiming to bring this peptide to the clinic. Moreover, Mr. Klein identified genomic variants that, today, help clinicians to prognosticate the course of sepsis.

MARK gallop, PhD

Co-Founder and Chairman of the Board

Mark Gallop is a veteran drug hunter, chemist and serial entrepreneur. He consults with emerging biotechnology companies in oncology, neuroscience, gastrointestinal disorders and drug design on drug discovery technologies and strategies. He served as Chief Scientific Officer and Director at BlueLight Therapeutics, company that uses a novel structure-function-based approach to develop new therapeutic molecules against challenging drug targets. He is also President at Light Horse Therapeutics, a small molecule drug discovery company employing tools from chemical and computational biology.  From 2012 to 2017 he served as the founding Chief Scientific Officer at Nurix, Inc., a venture-backed discovery company formed to explore drug development targeting ubiquitin ligase enzymes, with therapeutic applications spanning across oncology, immunology, inflammation and immuno-oncology. Prior to joining Nurix, he was Senior Vice President of Research and XenoPort, Inc., a company he co-founded in 1999 with the mission of improving the clinical utility of medicines by exploiting active transport mechanisms to optimize their pharmacokinetic properties. While at XenoPort, his team discovered Horizant™, a prodrug of gabapentin that was approved by the FDA in 2011 and the MHW in Japan in 2012 for the treatment of restless legs syndrome. Previously, Dr. Gallop was Senior Director of Combinatorial Chemistry at Affymax. He also served as executive in resident for 5AM Ventures. He is recognized as an early pioneer and international expert in solid-phase combinatorial chemistry. He was a recipient of the ACROS award of the Belgian Organic Synthesis Symposium in 1996 for his outstanding contributions to this field. He is an inventor on more than 100 issued or pending U.S., and PCT patents and an author of over 60 manuscripts in peer-reviewed journals. In 1994, he co-authored a landmark review of the then-emerging field of combinatorial chemistry that has subsequently become one of the most highly cited papers in chemistry. After undergraduate studies in New Zealand, he obtained his Ph.D. degrees in inorganic chemistry from the University of Cambridge and was a Lindemann postdoctoral fellow in the laboratories of Profs. Peter G. Schultz and Robert G. Bergman at the University of California, Berkeley.

Joanna Green, PhD

Ahren Innovation Capital Investment Professional

Joanna joined Ahren Innovation Capital from the Boston Consulting Group (BCG), where she worked on strategic projects within healthcare, insurance and the public sector.

Joanna holds a PhD in fetal immunology, focusing on childhood leukemia, and a First-Class Master’s and undergraduate degree from the University of Oxford.

Frederick beddingfield, md pHD

Chief Executive Officer

Frederick C. Beddingfield III is a physician-scientist and biotech entrepreneur. He is currently CEO and Board Director of Rubedo Life Sciences. He also serves as Chairman of the Board of Sagesse Bio and as a director of Cytrellis Biosystems. Previously he was an Executive Partner at Apollo Health Ventures, a longevity and age-related disease fund. He served as CEO and director of Kira Pharmaceuticals developing biologics for immunology, inflammation, and rare diseases from 2020 to 2023. He was founder, president, chief executive and member of the board of directors of Sienna Biopharmaceuticals Inc. and took the company public in 2017. Previously he served as Chief Medical Officer of Kythera Biopharmaceuticals, acquired by Allergan in 2015. Frederick worked at Allergan for 10 years (2003-2013) where he served in various roles including the Therapeutic Area Head of Dermatology and Chief Medical Officer Allergan Medical. He has led the development and approvals of global leading brands in medical dermatology, aesthetics, neurology, metabolic, and other therapeutic areas. These brands include Botox (cosmetic, hyperhidrosis, spasticity, and others), Juvederm, Voluma, Kybella, Latisse, Aczone, and Tazorac. Frederick has led four successful FDA advisory committees.

Since completing his training, Frederick has maintained a clinical and teaching practice at UCLA. He is a board-certified dermatologist and emergency medicine physician and fellowship trained in dermatologic surgery and cutaneous oncology. Frederick completed his medical degree with honors at UNC Chapel Hill, his residency and fellowship training at UCLA, and his PhD in Policy Analysis Research at RAND. He serves on the medical advisory board of the Children’s Skin Disease Foundation and Camp Wonder. He is on the board and co-founder of the Dermatology Summit and Dermatology Innovation Forum conferences, and a Board Trustee of Advancing Innovation in Dermatology, a non-profit organization.

Mario E. Lacouture, MD

Chief, Dermatology, NYU Langone Hospital; Professor of Medicine at NYU Grossman School of Medicine; Medical Director of the Symptom Management Program at the Perlmutter Cancer Center on Long Island

Before joining NYU Langone Health, Dr. Lacouture was an Attending Physician and Program Director of Oncodermatology and Research in the Dermatology Service at Memorial Sloan Kettering Cancer Center (MSKCC) in Manhattan. He was also a Professor in the Department of Dermatology at Weill Cornell Medicine in New York. He conducted his postdoctoral work at Brigham and Women’s Hospital in Boston, MA, an internship in General Surgery at Cleveland Clinic and residency in dermatology at The University of Chicago, IL. He received his M.D. degree from Javeriana University in Bogota, Colombia, where he grew up. Dr Lacouture began his career in Oncodermatology at The University of Chicago. During his first faculty appointment at Northwestern University, Dr Lacouture received a Zell Scholarship and a Career Development Award from the Dermatology Foundation, and established the first clinical program focused on dermatologic care in cancer patients and survivors. During this time, he initiated the first clinical trials in Oncodermatology, and described mechanisms and treatments on adverse events to novel cancer therapies, published in the Journal of Clinical Oncology and Nature Reviews Cancer.

Dr Lacouture founded the Skin Toxicity and the Oncodermatology Study Groups of the Multinational Association of Supportive Care in Cancer, is on the Guidelines Advisory Committee of the American Society of Clinical Oncology, and the Editorial Board of Cancer.Net. In 2012, CancerCare named Dr Lacouture as Physician of the Year for his contributions to the education of people living with cancer, and he has been selected as a Top Doctor in America and New York by Castle Connolly and New York Magazine since 2014. Dr Lacouture has published over 280 articles in peer-reviewed journals and is the author of Dr Lacouture’s Skin Care Guide for People Living With Cancer and Editor of the textbook Dermatologic Principles and Practice in Oncology. Dr Lacouture is the PI for numerous clinical trials aimed towards the treatment and understanding of adverse events related to cancer therapies and has received funding from the NIH to better understand these untoward events, with the goal of advancing cancer care through skin health.

Cory Hogaboam, PhD

Cedars-Sinai Professor of Medicine, Chronic Lung Diseases

Dr. Cory M. Hogaboam, PhD is a Professor of Medicine in the Women’s Guild Lung Institute at Cedars Sinai Medical Center. Dr. Hogaboam is also an Adjunct Professor of Pathology at the University of Michigan Medical School. His research group currently employs genomic, proteomic and bioinformatic approaches to analyze mechanisms contributing to fibrotic and immune system-directed responses in idiopathic pulmonary fibrosis (IPF), lung cancer, sarcoid, hypersensitivity pneumonitis, chronic obstructive pulmonary disease (COPD), and asthma utilizing human tissue- and blood-derived cells including fibroblasts, mesenchymal progenitors and various immune cell types that are typically present in abundance in these pulmonary diseases. His group also uses translational approaches through the development of humanized SCID mouse models of IPF, cancer, and asthma. He earned a Bachelor of Science degree in Zoology from the University of Calgary, AB, Canada in 1989. He also holds a Doctorate in Pharmacology (1993) from the same institution. Dr. Hogaboam then engaged in Postdoctoral training in Immunology at McMaster University, Hamilton, ON, Canada from 1993 to 1996. In 1996, Dr. Hogaboam joined the faculty of the Department of Pathology at the University of Michigan Medical School as a Visiting Scholar. He became a faculty member of the Department at the rank of Research Investigator in 1998, Assistant Professor in 2002, Associate Professor in 2004, and full Professor in 2008. Dr. Hogaboam joined the faculty at Cedars Sinai Medical Center in September of 2013. Hogaboam is a member of several professional organizations including the American Association of Immunologists, the American Thoracic Society, and the American Association of Allergy, Asthma and Immunology. He is presently serving on the editorial board of the American Journal of Respiratory and Critical Care Medicine and the Journal of Clinical Investigation Insight. Dr. Hogaboam has authored or co-authored approximately 281 peer-reviewed manuscripts and 31 book chapters. He has authored or co-authored 11 patents on therapeutic interventions for lung and liver. Dr. Hogaboam has received financial research support from the National Institutes of Health, American Lung Association, Canadian Institutes of Health Research, and several Industry sponsors.

Paul Insel, MD

University of California San Diego Emeritus Professor of Medicine and Pharmacology

Paul A. Insel received an M.D. from the University of Michigan and post-M.D. training at Boston City Hospital/Harvard Medical Service, the U.S. National Institutes of Health (NIH) and the University of California. San Francisco (UCSF). He served on the faculty at UCSF and subsequently joined UC San Diego (UCSD), where he is currently Distinguished Professor of Pharmacology and Medicine and Co-Director of the MD/PhD Training Program. Dr. Insel’s research efforts have focused on G-protein-coupled receptors (GPCRs), including studies of G-proteins and their effectors, signaling compartmentation in caveolae, GPCR expression and identification of novel GPCR therapeutic targets in a variety of disease settings. Dr, Insel is the author of over 470 scientific articles, including original studies, reviews and book chapters. Dr. Insel has been Editor-in-Chief of numerous scientific journals (including Journal of Clinical Investigation, American Journal of Physiology-Cell Physiology, and Molecular Pharmacology). He is currently Associate Editor of Pharmacological Reviews and Physiological Reviews and Editor-in-Chief of Annual Review of Pharmacology and Toxicology; U.S. Senior Editor, British Journal of Pharmacology and co-Head of Faculty, Faculty of 1000Prime in Pharmacology and Drug Discovery. Dr. Insel holds a Doc. Hon Causa from the University of Paris, is an elected member of the American Society for Clinical Investigation and the Association of American Physicians, a Fellow, American Association for the Advancement of Science and has received major awards from the American Association of MD/PhD Training Programs, American Physiological Society, Dutch Pharmacology Society, and American Society for Pharmacology and Experimental Therapeutics.

Jeff Jasper, PhD

Scientific Advisor, Drug discovery & Pharmacology

Jeff has over 25 years’ experience in the bio-pharmaceutical industry including
positions at Merck, Roche, Theravance and Cytokinetics. He has expertise in
molecular pharmacology, in vivo pharmacology and translational research with
industrial experience that includes leadership of discovery, preclinical and clinical
development projects. Jeff is a co-founder of Altos Therapeutics developing
gastrointestinal therapeutics (acquired by Takeda Pharmaceuticals in March 2017).

His academic activities include over 18 years as member of the Editorial Board for
the “American Journal of Physiology: Cell Physiology” and 12 years instructing the
“Molecular Pharmacology” course for the University of California, Berkeley
Extension. Jeff has published over 50 scientific articles in peer-reviewed journals. He
completed his bachelor’s degree in Chemistry at Cal Poly, San Luis Obispo, his Ph.D.
in Pharmacology at UCSD and his postdoctoral training at Stanford University.

Lidia Schapira, MD

Stanford School of Medicine Professor, Medical Oncology

Dr. Lidia Schapira is Associate Professor of Medicine at Stanford University School of Medicine and Director of Cancer Survivorship at the Stanford Comprehensive Cancer Institute. She graduated from Dartmouth Medical School and trained at the Beth Israel Hospital in internal medicine and completed a hematology and oncology fellowship at the Brigham and Women’s Hospital in Boston followed by a research fellowship in Aging at Harvard Medical School.​Dr. Schapira’s clinical focus is in treatment of breast cancer. She is a co-Principal Investigator in a longitudinal study of young women with breast cancer based at Dana Farber/Harvard Cancer Institute. Dr. Schapira has pioneered research and training in communication skills for cancer clinicians and initiatives designed to improve awareness of cancer research and clinical trials in underserved communities. She holds leadership roles in national and international societies (American Society of Clinical Oncology and Multinational Association of Supportive Care in Cancer) and serves as Editor-in-Chief of ASCO’s website for the public, Cancer.Net and Consultant Editor for Art of Oncology for the Journal of Clinical Oncology.​Dr. Schapira has contributed to volunteer efforts to improve cancer care globally through education and mentoring and served as past Chair of ASCO’s IDEA program. Throughout multiple clinical, editorial and educational activities, Dr. Schapira has devoted her career to improving the quality of life of patients and families with cancer through improvements in symptom management, improved communication and other strategies designed to support patients’ ability to manage the challenges associated with cancer.

Mark Pegram, MD

Stanford University School of Medicine Professor, Medical Oncology

Dr. Mark Pegram is the Suzy Yuan-Huey Hung Professor of Medical Oncology at the Stanford Cancer Institute. He currently serves as the Associate Director of Clinical Research at the Stanford Comprehensive Cancer Institute (SCCI), and Director of the Breast Oncology Program at Stanford. He also serves as the Associate Dean for Clinical Research Quality at the Stanford University School of Medicine. In collaboration with Dr. Dennis Slamon at UCLA, and scientists at Genentech, Inc. in South San Francisco, CA, Dr. Pegram played a significant role in the pre-clinical and early clinical development of trastuzumab (Herceptin®) for the treatment of HER2-positive breast cancer. In 2012, he was recruited to the SCCI from the Sylvester Comprehensive Cancer Center at the University of Miami School of Medicine, where he served as the Associate Director for Clinical Research, and acting Division Chief of Hematology/Oncology for a faculty of over 70 researchers. Pegram has chaired the U.S. Department of Defense Breast Cancer Research Program panel, and is the recipient of the NCI Director’s Service Award, the Sylvester Outstanding Cancer Research Award, the Hope Award from the HERS Breast Cancer Foundation, and is a Fellow of the Breast Cancer Research Foundation. His research focuses on new therapeutic strategies targeting HER2-positive breast cancers. Dr. Pegram was the lead author on the papers describing pre-clinical synergy between multiple chemotherapeutics and trastuzumab, and the first phase II clinical trial of trastuzumab plus chemotherapy. In addition, he was the senior author of the pivotal trial of letrozole plus lapatinib – leading to an FDA approval, and co-author of the pivotal trials of trastuzumab plus chemotherapy, and T-DM1, both published in the New England Journal of Medicine, and leading to FDA approvals.

Francesca Grisoni, PhD

Eindhoven University of Technology Assistant Professor, Molecular Machine Learning

Francesca Grisoni is an Assistant Professor at the Eindhoven University of Technology (Dept. Biomedical Engineering and Institute for Complex Molecular Systems), where she leads the Molecular Machine Learning team. After receiving her PhD in 2016 at the University of Milano-Bicocca, with a dissertation on machine learning for (eco)toxicology, Francesca worked as a data scientist and as a biostatistical consultant for the pharmaceutical industry. Later, she joined the University of Milano-Bicocca (in 2017) and the ETH Zurich (in 2019) as a postdoctoral researcher, working on machine learning for drug discovery and molecular property prediction. Her current research focuses on chemistry-centered AI, aiming to augment human intelligence in drug discovery at the interface between theory and application.second laboratory at the Buck Institute for Research on Aging, where she is Professor.

Ali Siam, CBO Rubedo

Ali SIAM

Chief Business Officer

Ali Siam has a unique combination of operating and strategy experience. He was previously CBO at Celmatix, where he led the team to multi-target R&D collaborations with Evotec SE and Bayer AG, and supported the development of their corporate and portfolio strategy. Prior to Celmatix, he led corporate strategy, R&D prioritization, portfolio strategy, and due diligence engagements for biopharma, diagnostic, healthcare services, and institutional investor clients across therapeutic areas (TAs) as a team leader at L.E.K. Consulting. He also led collaborations in a whitespace team at AbbVie, in addition to developing go-to-market, launch, and lifecycle management strategy across TAs. Ali also has strategic marketing and R&D experience from his time at Johnson & Johnson, and holds an MBA from Boston College and a BS in Mechanical Engineering from Northeastern University.

Marco Demaria, PhD

University of Groningen European Research Institute for the biology of Ageing

Marco Demaria is a Professor of Cellular Ageing and Senescence at the Medical Faculty of the University of Groningen (RUG) and the Group leader of laboratory of Cellular Senescence and Age-related Pathologies at the European Research Institute for the Biology of Ageing (ERIBA, Groningen, Netherlands). He obtained his PhD in Molecular Medicine at the University of Torino, Italy, and trained as postdoc in the laboratory of prof. Judith Campisi at the Buck Institute for Research on Aging, California USA. His research is focused towards understanding the role of cellular senescence in different physiological and pathological contexts with the goal to identify novel interventions to extend healthy longevity. His laboratory covers fundamental, translational and clinical aspects, and is funded by several intramural and extramural agencies. His work has been published in top journals and he is regularly in the top 1% of most cited researchers in the field of molecular biology. Since 2023, Prof. Demaria also serves as the Director of the Mechanisms of Health, Ageing and Disease (MoHAD) of the University Medical Center Groningen. Additionally, Prof. Demaria is the President of the International Cell Senescence Association and Editor in Chief of the Natural Publishing Group journal npj aging

Marco Quarta, PhD

Co-Founder and Chief Scientific Officer

Marco Quarta, PhD, he is the founding CEO and President of Rubedo that he led from 2018 to 2024.  He received his doctorate degree in Biotechnology from the University of Bologna and a Ph.D. in Neuroscience from the University of Padua. He completed a post-doc in Aging and Stem cell Biology in the lab of Prof. Thomas Rando at Stanford University. He continued his work at Stanford directing a research team at the Center for Tissue Regeneration, Repair, and Restoration at the VA Hospital in Palo Alto, CA. While there, he established a translational program in regenerative medicine. He has over 35 publications and patents in the field of aging, stem cells, regenerative medicine, and rejuvenation.Marco also co-founded Wetware Concepts, YEBN, and Turn Biotechnology and served as an executive board member of the European Federation of Biotechnologies. He currently sits on the advisory board of the California Institute for Regenerative Medicine (CIRM) Calpoly Bridge program, and the advisory board at the Center for Healthcare Innovation. Marco is a member of the Paul F Glenn Center for the Biology of Aging Studies at Stanford University, one of the most prestigious institutions supporting the science of aging. He is President and co-founder of the scientific organization Phaedon Institute, focused on Longevity Medicine.